白物质管道完整性与前额执行功能在患有重大抑郁障碍的非老年成人患者中的关联
Joo-Yeon Ahn1, Youbin Kang2, Aram Kim2
1Department of Psychiatry, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Republic of Korea.
Psychiatry investigation
|February 7, 2024
概括
重度抑郁症 (MDD) 与白质完整性降低有关,特别是在大子 (FMajor) 中,影响成人的反应时间等执行功能. 这表明受损的结构连接有助于MDD的认知功能障碍.
科学领域:
- 神经成像是一种神经成像.
- 神经科学是一个神经科学.
- 精神病学是一个精神病学.
背景情况:
- 重度抑郁症 (MDD) 是一种普遍存在的心理健康状况.
- 认知缺陷,特别是执行功能,在MDD患者中很常见.
- 白质完整性的改变可能是MDD的认知功能障碍的基础.
研究的目的:
- 为了研究白质管道完整性和MDD的成年非老年患者的前额执行功能之间的关联.
- 为了比较MDD患者和健康对照 (HCs) 之间的扩散张力成像 (DTI) 参数.
- 在两组中探索白质完整性和认知表现之间的相关性.
主要方法:
- 扩散张力成像 (DTI) 和由底层解剖学 (TRACULA) 约束的通道被用于评估白质完整性.
- 进行认知功能测试,包括Stroop任务.
- 统计分析包括ANCOVA和Pearson的部分相关性,对年龄,性别和教育进行控制.
主要成果:
- 与HC相比,MDD患者在几个白质通道中显著减少了轴向扩散率 (AD) 和平均扩散率 (MD).
- 具体来说,AD降低观察到大 (FMajor),皮质脊髓 (CST) 和其他带.
- 在MDD患者中的FMajor中,Stroop任务响应时间和AD之间发现了负相关性.
结论:
- 大子 (FMajor) 的结构连接受损与非老年MDD患者的认知功能障碍有关.
- 这些发现突出了白质异常在MDD认知缺陷病理生理学的作用.
- DTI可以作为一种有价值的工具来了解MDD的神经生物学基础.
更多相关视频
10:43Developing Neuroimaging Phenotypes of the Default Mode Network in PTSD: Integrating the Resting State, Working Memory, and Structural Connectivity
Published on: July 1, 2014
15.1K
08:20MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
Published on: August 11, 2015
13.9K
相关概念视频
Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
Cognitive Development During Adulthood
1.4K
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
1.4K
Alzheimer Disease l: Introduction
21
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
21
Alzheimer Disease ll: Pathophysiology
35
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
35
Dementia l: Introduction
35
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
35
